Indonesia’s $9B Chinese Fighter Jet Deal Shocks the World

Indonesia’s $9B Chinese Fighter Jet Deal Shocks the World

  • Indonesia will buy at least 42 Chinese Chengdu J-10C fighters (a ~$9 billion commitment in the 2026 budget), marking the country’s first major arms purchase from Beijing.
  • “They will be flying over Jakarta soon,” said Defense Minister Sjafrie Sjamsoeddin. The purchase is part of Indonesia’s Trisula Nusantara modernization push. Jakarta also ordered 42 French Dassault Rafales ($8.1B) and 48 Turkish KAAN jets as it replaces aging F-16s and Sukhois.
  • Shift to multipolar procurement: Experts note Indonesia’s “bebas-aktif” non-aligned policy means buying the best platforms regardless of origin [1]. Analyst Beni Sukadis warns that the J-10 deal “could be read as a shift in Indonesia’s security orientation amid China’s growing influence” in Southeast Asia. But many analysts emphasize Jakarta’s focus on capability and sovereignty over bloc allegiances [2].
  • Chinese view: PLA and Chinese officials praise the J-10’s performance. State media quotes a Chinese military researcher calling the J-10 “cost-effective” with outstanding radar and missiles, combat-proven in recent conflicts. China’s defense ministry says it is “willing to share the achievements of China’s equipment development with friendly countries” to promote regional stability.
  • Market impact: Western defense stocks held firm. Lockheed Martin (NYSE: LMT) closed around $495 on Oct. 17 [3] and Boeing (NYSE: BA) about $212 [4]. By contrast, Saab AB (Sweden; maker of the Gripen fighter) dropped ~4.4% to 461.9 SEK [5] on Oct. 17, as analysts note competition from Chinese jets. Tech analysis site TS2.tech observes Indonesia had been evaluating Saab’s Gripen, but had already locked in Rafales and eyed U.S. F-15s. The fighter jet market is heating up worldwide, with Pakistan, Iran and others showing interest in China’s J-10.
  • Next steps: The exact contract details and delivery schedule remain under wraps. Indonesian officials say budget approvals are done, but reports suggest the deal might be financed partly by loans. Deliveries could begin in the late 2020s, with pilot training in China by 2026 [6]. Jakarta insists this deal won’t undermine its ties with the U.S. or France – as one analyst notes, Indonesia is now buying Chinese jets and continuing Rafales and Turkish planes, “yet maintains ties with the United States” [7].

Indonesia’s abrupt pivot to Chinese fighters has captured global attention. Defense analysts say it underscores Jakarta’s insistence on strategic autonomy. “Foreign actors can spread disinformation, but at the end of the day, Indonesia buys what it chooses,” writes analyst Muhammad Zulfikar Rakhmat [8]. In practice, Jakarta is “quietly demonstrating that strategic autonomy is possible” – fielding the latest jets from East and West while balancing great-power pressures [9]. For now, Southeast Asian neighbors and global arms makers will be watching closely how this deal unfolds and how it reshapes the region’s airpower balance.

Sources: Official statements and budget documents; reporting from AP and The Diplomat [10]; expert analysis in Asia Times and FlightGlobal [11] [12]; market data from Reuters and Investing.com [13] [14]; industry commentary from TS2.tech.

Indonesia Setujui Pembelian Jet Tempur Canggih J-10C dari China Senilai Rp139 Triliun ✈️🇮🇩

References

1. asiatimes.com, 2. asiatimes.com, 3. www.investing.com, 4. www.investing.com, 5. www.reuters.com, 6. defencesecurityasia.com, 7. asiatimes.com, 8. asiatimes.com, 9. asiatimes.com, 10. thediplomat.com, 11. asiatimes.com, 12. www.flightglobal.com, 13. www.investing.com, 14. www.reuters.com

A technology and finance expert writing for TS2.tech. He analyzes developments in satellites, telecommunications, and artificial intelligence, with a focus on their impact on global markets. Author of industry reports and market commentary, often cited in tech and business media. Passionate about innovation and the digital economy.

Rani Therapeutics (RANI) Stock Surges 150% on $1B+ Chugai Collaboration – Analysts Weigh In
Previous Story

Rani Therapeutics (RANI) Stock Surges 150% on $1B+ Chugai Collaboration – Analysts Weigh In

Sellas Life Sciences (SLS) Stock Rallies on Promising Leukemia Data – Analysts Eye Triple-Digit Upside
Next Story

Sellas Life Sciences (SLS) Stock Rallies on Promising Leukemia Data – Analysts Eye Triple-Digit Upside

Stock Market Today

  • Mobileye (MBLY) Valuation Review After 30% YTD Slide
    October 18, 2025, 5:32 PM EDT. Mobileye Global MBLY has slipped about 3% as momentum cools and the stock sits roughly 30% lower for the year. The setup raises the question of whether the current level offers an attractive entry point, despite a 1-year total return near 10%. A widely cited narrative pegs fair value around $19.67, signaling undervaluation as catalysts build around partnerships and product momentum-most notably with Uber/Lyft integration via Mobileye Drive and a new European OEM engagement. Yet the stock trades at about 5.9x sales, well above the industry/peer averages and our implied 4.5x fair ratio, suggesting a premium despite weakness. Investors should weigh growth upside against auto-production/tariff risks and execution on partnerships.
  • United Therapeutics Valuation After 48% Rally: Is the Upside Still Untapped?
    October 18, 2025, 4:46 PM EDT. United Therapeutics (UTHR) has jumped ~48% over the past three months, lifting its pharma/biotech peers' attention. The rally has pushed the stock toward the sector's top tier as investors weigh a three-year TSR of about 98% and steady revenue growth. With a recent fair-value narrative suggesting a $492.85 target, bulls argue the stock remains undervalued relative to growth prospects, aided by a pipeline spanning progressive fibrosis programs, next-gen delivery platforms, and organ manufacturing initiatives (including xenotransplant/3D printing). Still, the upside faces key risks from upcoming trial readouts and rising competition. The question for investors: is the market already pricing in future milestones, or does a longer runway for margin expansion and new revenue streams remain? Build your own view with the full narrative.
  • Novo Nordisk Valuation Under Scrutiny Amid Share-Price Pressure
    October 18, 2025, 4:44 PM EDT. Novo Nordisk (NYSE:NVO) faces renewed investor scrutiny as the stock trades near $54.37, down ~7% in a month and ~15% over 3 months. Year-to-date declines around 38% have raised questions about momentum and growth optionality. Some analyses argue the shares remain undervalued versus a fair value around $120+, citing durable economics and optionality in the pipeline. Yet risks such as US drug-pricing reforms and adoption of next-gen therapies temper the upside. The debate hinges on whether the market has already priced in growth or a broader pullback in risk appetite. For investors, Novo Nordisk represents a high-quality compounder with potential upside if pipeline wins and margin resilience materialize, but valuation remains sensitive to policy shifts and execution outcomes.
  • ETH Whales Back Mutuum Finance: Is MUTM the Next DeFi Boom?
    October 18, 2025, 4:28 PM EDT. Seasoned ETH investors are diversifying into high-potential DeFi plays as Ethereum stays range-bound below $4,000. Mutuum Finance (MUTM) has caught attention in Phase 6 of its presale, with over 70% sold and more than $17.6 million raised. MUTM combines a novel dual-lending model-Peer-to-Peer and Peer-to-Contract liquidity pools-to deliver lending, borrowing and real-world utility within a single ecosystem. Support from a growing community and strong presale demand have fueled chatter that MUTM could be the next crypto star to explode, even as ETH targets higher levels. Analysts note Ethereum's long-term bullish thesis remains intact, while opportunistic investors eye MUTM as a potential complement to legacy positions and a gateway to DeFi exposure.
  • High-Interest Credit Card Debt: The No. 1 Habit Destroying Retirement Dreams
    October 18, 2025, 4:12 PM EDT. High-interest debt is destroying retirement plans. U.S. credit card balances rose from $787B in 2021 to $1.2T in 2025, with APR around 25%. Debt grows faster than many can pay, pushing households to rely on cards for everyday expenses even in retirement. Data show 41% of households headed by someone 65-74 carry debt; average balances by generation: Gen X $9,600, Millennials $6,961, Boomers $6,795. A 55-year-old with $9,600 at 25% APR paying $300/month would need 54 months and incur about $6,384 in interest; invested instead, that amount could grow substantially over 10-20 years at ~7% returns. Freeing up those payments can bolster retirement savings. Consider options like a consolidation loan to get debt under control and then invest for retirement, with steps outlined below.
Go toTop